Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1872]

Using PARP inhibitors to improve quality of life for patients with metastatic...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Breast cancer highlights from ESMO 2019

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer highlights from ESMO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer

Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA )

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and...

Prof George Sledge - Stanford Health Care, Stanford, USA

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy ( Prof George Sledge - Stanford Health Care, Stanford, USA )

Comment: Keynote 522 trial

Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy

Comment: Keynote 522 trial ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in...

Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California )

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR...

Prof George Sledge - Stanford Health Care, Stanford, USA

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer ( Prof George Sledge - Stanford Health Care, Stanford, USA )

Comment: CDK4/6 inhibitors in advanced breast cancer

Prof Nadia Harbeck - University of Munich, Munich, Germany

Comment: CDK4/6 inhibitors in advanced breast cancer ( Prof Nadia Harbeck - University of Munich, Munich, Germany )

Immunotherapy added to chemotherapy improves pathological complete response in...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

More from ecancer